echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return”?

    Wanchun Pharmaceutical’s rejection of new drug listing, will Hengrui be implicated in the development of new drugs, will it be a “point of no return”?

    • Last Update: 2022-01-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Can Hengrui break through the “nine deaths and a lifetime” of new drug research and development?

    Wanchun Pharmaceutical’s core product Punablin was rejected from listing in the United States, plummeting 60%, and its market value fell to less than US$200 million
    .
    The partner Hengrui was also implicated, and the stock price fell

    .

    The research and development of new drugs is risky, full of uncertainties, and performance in a short period of time is under pressure.
    .
    .
    In desperation, Hengrui's innovation and transformation is also "flexible"

    .

    Punabulin’s listing application was rejected.
    Will the 1.
    3 billion cooperation be affected?

    Punabulin’s listing application was rejected.
    Will the 1.
    3 billion cooperation be affected?

    On the evening of December 1, 2021, Wanchun Medicine issued an announcement stating that the listing application of Pranabrin for the treatment of chemotherapy-induced neutropenia (CIN) received a complete response letter (CRL) from the US FDA
    .

    The FDA pointed out in the review opinion that the data from only one registered clinical study (Prinabulin 106 Phase III clinical study) is not enough to fully confirm the clinical value of Prinabulin, and a second controlled registered clinical study is needed to provide sufficient information.
    The evidence supports the NDA (New Drug Application) for the prevention of chemotherapy-induced neutropenia

    .
    Based on current data, the FDA is unable to approve the NDA

    .

    Pranabrin is a First-In-Class new drug developed by Wanchun Pharmaceutical.
    It is a selective immunomodulatory microtubule binding agent (SIMBA) that can be used to prevent chemotherapy-induced neutropenia (CIN) and treat Clinical development of advanced non-small cell lung cancer (NSCLC) and other solid tumors

    .

    In June 2020, Wanchun Medicine announced that the interim analysis of the PROTECTIVE-2 Phase III clinical trial of Pranabrin for severe neutropenia (CIN) caused by chemotherapy has reached the primary research endpoint
    .
    Since then, Pranabrin has successively obtained breakthrough therapy certifications from NMPA and FDA

    .

    Public information shows that Wanchun Medicine was established in 2010, and all of the company's products have not yet been commercialized
    .
    The stranding of the NDA will undoubtedly affect the commercialization of Wanchun Pharmaceutical's Pranabrin

    .

    Currently, Wanchun Pharmaceutical is preparing a response to the FDA's review comments, and plans to apply for a communication meeting with the FDA
    .
    Dr.
    Huang Lan, the co-founder, chairman and CEO of Wanchun Pharmaceutical, also publicly stated that the company firmly believes that the combined application of punabulin and G-CSF has great potential to improve the level of CIN treatment

    .
    At the same time, the company is still confident in the efficacy and safety data of prinabulin combined with G-CSF in preventing CIN, and plans to maintain close communication and cooperation with the FDA and consider adding a clinical study

    .

    According to the "Science Innovation Board Daily" report, it may be caused by the clinical impact of the epidemic in Eastern Europe.
    A confirmatory phase III clinical study is needed.
    It is not expected to be too long.
    Time to market will be delayed

    .

    The cooperation between Hengrui and Wan Chun is also Sun Piaoyang's first big move after his return, so it has attracted much attention
    .
    On August 25, 2021, Hengrui Pharmaceuticals and Wanchun Pharmaceutical’s subsidiary Dalian Wanchun signed the "Capital Increase Agreement" and the "Punabulin Product Cooperation Agreement".
    Hengrui Pharmaceuticals intends to acquire shares in Dalian Wanchun with self-raised funds.
    Obtained the joint development and exclusive commercialization rights of punabulin in the Greater China region

    .

    According to the agreement, Hengrui Pharmaceuticals will pay Wanchunbulin down payment plus milestone fees to a total of no more than 1.
    3 billion yuan, including a one-time payment of Wanchunbulin down payment of 200 million yuan, and when the corresponding R&D and commercialization milestones are reached Pay a total of no more than 1.
    1 billion yuan to Wanchun Bulin

    .

    It is understood that Hengrui has paid a down payment of 200 million yuan to Dalian Wanchun, and has not carried out any clinical research on pranabulin
    .
    Regarding the 100 million yuan equity investment to Dalian Wanchun as stipulated in the "Capital Increase and Shareholding Agreement", the company has not yet paid the payment and the equity has not yet been delivered

    .

    Hengrui pointed out in today's announcement that the two parties will further negotiate in the near future regarding product follow-up research and development plans and cooperation matters
    .

    Buy, buy, buy, Hengrui will “spend the money” on R&D

    Buy, buy, buy, Hengrui will “spend the money” on R&D

    Hengrui is not at peace this year, and its market value has evaporated by more than 300 billion yuan
    .
    After the mid-year report was released, revenue growth hit a record low since 2003

    .
    Some time ago, Hengrui announced in its third quarter report that both revenue and net profit growth have declined; the first three quarters of net profit growth have turned negative, which is the first negative growth in its net profit since 2010

    .

    The main reason for the sluggish performance was the decline in sales of Hengrui's generic drugs due to the impact of national and local volume purchases
    .
    In terms of generic drugs, the types involved in the third and fourth batches of centralized procurement have already implemented centralized procurement.
    Industrial Securities predicts that Hengrui's fifth batch of centralized procurement will also begin to implement centralized procurement, which is revenue from generic drugs.
    Bring greater pressure

    .

    In terms of innovative drugs, Hengrui’s main product PD-1 will begin to implement the negotiated price of medical insurance from March 1, 2021, with a reduction of 85%, causing revenue growth to be under pressure; in addition, other newly approved innovative drugs such as fluorine Zopali and Hytrobopar have just been listed and are in a ramp-up period, and their short-term contribution to revenue is limited
    .

    In the darkest moment, transformation is urgent.
    Hengrui redefines innovation and internationalization in terms of R&D strategy

    .
    The first is to explore new targets, take on higher R&D risks, and solve unmet clinical needs; the second is to fully explore the potential of the targets under research in a variety of indications and explore new indications; the third is to deploy a variety of diseases in the field of treatment Products with different mechanisms of action form complements and gains; fourth, multiple platform technologies support in-depth research, and continue to produce global equity projects; fifth, strengthen cooperation with biomedical companies, improve pipelines, and accelerate internationalization; sixth, establish overseas clinical teams , Cultivate internal capabilities and accelerate overseas clinical development and product launches

    .

    Among them, Hengrui's more frequent action is to spend a lot of money to buy promising products from other pharmaceutical companies
    .
    Up to now, Hengrui has introduced 4 oncology drugs this year, mainly Yingli Pharmaceutical for the PI3kδ inhibitor YY-20394, Dalian Wanchun GEF-H1 activator punabulin, and Tianguangshi for the third-generation anti-CD20 Antibody MIL62, CStone's anti-CTLA-4 monoclonal antibody CS1002

    .

    In response to changes in the external environment, Hengrui has continued to increase its own pipeline R&D investment while also increasing its efforts in cooperation and introduction.
    Hengrui is accelerating its progress on the road of innovation and transformation

    .

    The industry also understands that such as Hengrui’s authorized introduction and cooperation between domestic pharmaceutical companies, new drug R&D investment is large, the cycle is long, and the risk is high.
    Products bought from other companies will soon be marketed.
    Compared with independent research and development, the investment will undoubtedly get a faster return on investment.
    One way

    .
    Coupled with the recent release of CDE's guidelines for clinical research and development of oncology drugs, it has also forced innovative pharmaceutical companies to develop their R&D capabilities and R&D results with high quality

    .

    The chief financial officer is replaced, and R&D investment is capitalized to avoid risk?

    The chief financial officer is replaced, and R&D investment is capitalized to avoid risk?

    The urgency of transformation and the "three highs" of innovation itself have also brought many pharmaceutical companies into trouble.
    As we all know, the high investment, high risk, and long cycle characteristics of pharmaceutical research and development make the road to market a new drug even more ups and downs

    .
    At the operating level, in order to make the financial report look better, some domestic pharmaceutical companies have adopted the method of capitalization of R&D expenditure

    .

    Regarding the treatment of R&D expenditures, Hengrui, which has always been conservative, is also beginning to change.
    On November 19, 2021, Hengrui also issued an announcement stating that for drug R&D projects that require clinical trials, the development phase expenditure means that drug R&D enters III.
    The R&D expenditures after the phase of clinical trials (or critical clinical trials) are included in the development expenditures when the expenditures in the development phase are assessed to meet the capitalization conditions

    .

    Coincidentally, recently, an article titled "Microchip Bio-Financial Radical Escort Refinancing" also pointedly pointed out that Microchip's R&D investment was over-capitalized and adopted a radical accounting treatment policy for R&D investment
    .
    In this regard, Microchip Technology issued a special clarification announcement stating that the company’s accounting policy for the capitalization of R&D expenditures does not differ significantly from that of companies in the same industry, and that the accounting policy remains consistent before and after the company’s listing

    .

    In the first half of 2021 and the first half of 2020, the capitalization ratio of Microchip's R&D investment was 43.
    17% and 39.
    85%, respectively.
    Among the listed companies in the same industry, Betta Pharmaceuticals, Tebao Bio, Xinlitai, etc.
    have capitalized R&D investment The proportions are not low

    .

    Regarding the capitalization of R&D investment, on the evening of November 29, Hengrui received a supervisory work letter from the Shanghai Stock Exchange to clarify supervisory requirements on related matters
    .
    According to industry insiders, this is nothing more than clarifying that the requirements for capitalization must be carefully assessed and the collection of R&D expenditures must be accurate and complete.
    This is part of the exchange’s daily performance of duties and does not involve administrative penalties

    .

    The capitalization of R&D expenditures preferred by pharmaceutical companies, industry sources said, is simply understood as balancing current expenditures
    .
    This is because if R&D expenses are directly included in the statement at one time, it highlights that current expenditures are relatively large, and corporate profits are relatively small, which will also affect corporate valuation

    .
    Capitalization means to amortize R&D expenses in multiple periods, which can reduce current expenditures and make performance statements more balanced

    .
    However, not all expenses are suitable for capitalization

    .

    The relevant person in charge of Hengrui also revealed to the public that “In recent years, Hengrui has continued to increase investment in research and development, and at the same time implemented informatization and refined management of research and development projects.
    With the accumulation of research and development strength and experience, the company has established an expert group Regularly evaluate R&D projects, and adjust R&D projects in a timely manner based on the evaluation results, business development needs and market conditions, reducing the uncertainty of R&D results and commercialization results

    .
    ” And according to the announcement, compared with other companies, Heng In terms of capitalization of R&D expenditures, Rui's timing selection is still conservative

    .

    It is worth noting that with the adjustment in the general direction, the Chief Financial Officer of Hengrui has also adjusted
    .
    On November 12, Hengrui Chief Financial Officer Zhou Song applied to resign from the position of Chief Financial Officer of the company due to personal reasons, and Liu Jianjun took over.
    The industry speculates that it may be related to the adjustment of the capitalization of R&D investment

    .

    Generic drugs have low profits and they spend great efforts on R&D.
    R&D risks are difficult to evade.
    However, this year’s performance growth rate is not as fast as expected, and the stock market’s response is also strong

    .
    Changing ideas on reports may also be an important part of Hengrui's many changes

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.